The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

The French pharmaceutical group’s board is scheduled to meet to discuss the planned transaction and finalize measures with CD&R to protect jobs and local plants, the people said, asking not to ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US ...

Clayton Dubilier & Rice is close to completing a deal to buy control of Sanofi’s (NASDAQ:SNY) consumer health unit after signing social commitments with the French government, Bloomberg News ...

In September, Bloomberg reported that Sanofi had received two separate bids from CD&R and rival PAI Partners for the Opella unit. CD&R has kept away interest from rival PAI Partners for the unit ...

Citi was advising CD&R on the sale, while Goldman Sachs and Morgan Stanley were sellside advisors. JPMorgan Chase & Co. advised France’s PAI Partners on a rival bid. It’s unclear whether the ...

French pharmaceutical group Sanofi and US private equity firm Clayton Dubilier & Rice (CD&R) have entered exclusive negotiations regarding the partial takeover of Sanofi subsidiary Opella.

The proposed transaction would see the French pharmaceutical company sell a controlling 50% stake in Opella--home to brands such as Allegra, Dulcolax and IcyHot--to CD&R, French state-owned ...

Sanofi said on Monday (Oct 21) it had entered exclusive talks for the sale of a 50 per cent controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice ...